Advanced search
Publication Cover
Acta Cardiologica Volume 77, 2022 - Issue 4
Submit an article Journal homepage
127
Views
6
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Frequency and predictors of no-reflow phenomenon in patients with COVID-19 presenting with ST-segment elevation myocardial infarction

Arda GülerDepartment of Cardiology, Health Sciences University, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5763-6785
ORCID Icon,
İsmail GürbakDepartment of Cardiology, Health Sciences University, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
,
Cafer PançDepartment of Cardiology, Health Sciences University, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
,
Ahmet GünerDepartment of Cardiology, Health Sciences University, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0001-6517-7278
ORCID Icon &
Mehmet ErtürkDepartment of Cardiology, Health Sciences University, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
Pages 313-321 | Received 29 Mar 2021, Accepted 14 May 2021, Published online: 31 May 2021

References

  • Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639.
  • Koutsoukis A, Delmas C, Roubille F, et al. Acute coronary syndromes in the era of SARS-CoV-2 infection: a registry of the French group of acute cardiac care. CJC Open. 2021;3(3):311–317.
  • Reffelmann T, Kloner RA. The “no-reflow” phenomenon: basic science and clinical correlates. Heart. 2002;87(2):162–168.
  • Choudry FA, Hamshere SM, Rathod KS, et al. High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020;76(10):1168–1176.
  • Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25:2000045.
  • Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177.
  • World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance; 2020. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf
  • Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041.
  • Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
  • Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (sars-cov-2; covid-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020;15(6):e0234765–19.
  • Li J, Yan R, Zhai Y, et al. Chest CT findings in patients with coronavirus disease 2019 (COVID-19): a comprehensive review. Diagn Interv Radiol. 2020;10.
  • Allencherril J, Jneid H, Atar D, et al. Pathophysiology, diagnosis, and management of the no-reflow phenomenon. Cardiovasc Drugs Ther. 2019;33(5):589–597.
  • Yang L, Cong H, Lu Y, et al. Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine (Baltimore). 2020;99(26):e20152.
  • Jacobs AK, Ali M, Best PJ, et al. Temporary emergency guidance to STEMI systems of care during the COVID-19 pandemic: AHA’s mission: lifeline. Circulation. 2020;142(3):199–202.
  • Vrachatis DA, Deftereos S, Stefanini GG. STEMI in COVID-19 patients: thrombolysis-first approach could yield more risk than benefit. Eur Heart J. 2020;41(42):4141–4142.
  • Huang B, Xu C, Liu H, et al. In-hospital management and outcomes of acute myocardial infarction before and during the coronavirus disease 2019 pandemic. J Cardiovasc Pharmacol. 2020;76(5):540–548.
  • Kwok CS, Gale CP, Kinnaird T, et al. Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction. Heart Br Card Soc. 2020;106(23):1805–1811.
  • Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7:438–440.
  • Poredos P, Jezovnik MK. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. Int Angiol J Int Union Angiol. 2007;26:306–311.
  • Koupenova M, Clancy L, Corkrey HA, et al. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res. 2018;122(2):337–351.
  • Zhang S, Diao J, Qi C, et al. Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis. BMC Cardiovasc Disord. 2018;18(1):75.
  • Moriya J. Critical roles of inflammation in atherosclerosis. J Cardiol. 2019;73(1):22–27.
  • Zhou H, He X, Zhuang S, et al. Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention. World J Emerg Med. 2014;5(2):96–102.
  • Abduganieva E, Gafner N. Endothelial dysfunction as a predictor of hypercoagulable disorders in patients with COPD. Eur Respir J. 2019;54:PA628.
  • Erkol A, Oduncu V, Turan B, et al. The value of plasma D-dimer level on admission in predicting no-reflow after primary percutaneous coronary intervention and long-term prognosis in patients with acute ST segment elevation myocardial infarction. J Thromb Thrombolysis. 2014;38(3):339–347.
  • Shah S, Shah K, Patel SB, et al. Elevated d-dimer levels are associated with increased risk of mortality in coronavirus disease 2019. Cardiol Rev. 2020;28(6):295–302.
  • Berger JS, Kunichoff D, Adhikari S, et al. Prevalence and outcomes of D-dimer elevation in hospitalized patients with COVID-19. ATVB. 2020;40(10):2539–2547.
  • Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859–1865.
  • Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:1–3.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.